Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -123% Improvement Relative Risk c19early.org/e Karimpour-Razkenari et al. Aspirin LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? Retrospective 478 patients in Iran (February - May 2020) Higher mortality with aspirin (p=0.008) Karimpour-Razkenari et al., J. Pharmaceutical Care, doi:10.18502/jpc.v10i3.10790 Favors aspirin Favors control
Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19
Karimpour-Razkenari et al., Journal of Pharmaceutical Care, doi:10.18502/jpc.v10i3.10790
Karimpour-Razkenari et al., Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized.., Journal of Pharmaceutical Care, doi:10.18502/jpc.v10i3.10790
Oct 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 478 moderate to severe hospitalized patients in Iran, showing higher mortality with aspirin treatment. Authors note confounding by indication for aspirin treatment. This study is excluded in the after exclusion results of meta analysis: substantial unadjusted confounding by indication likely.
risk of death, 123.2% higher, RR 2.23, p = 0.008, treatment 39 of 90 (43.3%), control 64 of 363 (17.6%), adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Karimpour-Razkenari et al., 3 Oct 2022, retrospective, Iran, peer-reviewed, median age 58.5, 9 authors, study period 23 February, 2020 - 23 May, 2020.
Contact: ghazaeianm@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: 2022 Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19 Elahe Karimpour-Razkenari1, Javad Boskabadi1, Monireh Ghazaeian2*, Hamidreza Samaee1, Hanieh Azizi1, Fatemeh Esfandiari3, Seyed Abdollah Mousavi4, Sahar Fallah5, Sekineh Talebi6 Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran. 1 Pharmaceutical Sciences Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran. 2 School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran. 3 Department of Pediatric Surgery, Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran. 4 Department of Biostatistic, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran. 5 Department of Nursing, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran. 6 Received: 2022-03-29, Revised: 2022-06-10, Accepted: 2022-06-11, Published: 2022-09-30 ARTICLE INFO ABSTRACT Article type: Original article Background: The coronavirus disease 2019 (COVID-19) is highly contagious and has turned into a global health problem. In this study, we investigated the role of clinical and laboratory characteristics along with administered therapeutic agents in patients with COVID-19, and identified some effective factors on the mortality of these individuals. Keywords: COVID-19; Mortality; Epidemiology Methods: In this retrospective study, we evaluated the data from all the hospitalized patients who had been diagnosed with COVID-19 between February 23 and May 23, 2020. The data were obtained from medical records. Additionally, a checklist was used to record demographic, clinical, laboratory, imaging, and treatment data for each patient. Results: Totally, 478 patients were involved in this study, and their median age was 58.5 years. Of these, 53.3% patients were male. The most common pre-existing underlying disease was hypertension (37.9%), and the mortality group had significantly more comorbidities (85.4%). Higher neutrophil lymphocyte ratio (NLR), lymphopenia, and reduced hemoglobin were more frequent in the mortality group (p < 0.001). Similarly, the need to be admitted to the intensive care unit was significantly greater in the mortality group (p<0.001). The most frequently administered therapeutic regimens included hydroxychloroquine and lopinavir/ritonavir, which did not have any correlation with survival outcome. Conclusion: Older age, opioid addiction, cardiovascular disease, kidney disease, baseline NLR and hemoglobin, and ICU admission were independently associated with COVID-19 mortality. On the other hand, hydroxychloroquine and lopinavir/ritonavir indicated no beneficial effects on patients’ outcome. J Pharm Care 2022; 10(3): 103-114. Please cite this paper as: Karimpour-Rrazkenari E, Boskabadi J, Ghazaeian M, Samaee H, Azizi H, Esfandiari F, et al. Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19. J Pharm Care 2022; 10(3): 103-114.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit